Your browser doesn't support javascript.
loading
Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer.
Brown, Kristin K; Spinelli, Jessica B; Asara, John M; Toker, Alex.
Afiliação
  • Brown KK; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. atoker@bidmc.harvard.edu kristin.brown@petermac.org.
  • Spinelli JB; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Asara JM; Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.
  • Toker A; Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.
Cancer Discov ; 7(4): 391-399, 2017 04.
Article em En | MEDLINE | ID: mdl-28255083

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Resistencia a Medicamentos Antineoplásicos / Neoplasias de Mama Triplo Negativas / Antineoplásicos Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Resistencia a Medicamentos Antineoplásicos / Neoplasias de Mama Triplo Negativas / Antineoplásicos Idioma: En Ano de publicação: 2017 Tipo de documento: Article